456 Molecular characteristics of gynaecological cancer patients in the IMPRESS-Norway trial – a national prospective, non-randomized clinical trial evaluating the efficacy of anti-cancer drugs on new indications

Author(s)

• Cecilie Fredvik Torkildsen
• Kristina Yvonne Kathe Lindemann
• Katharina Bischof
• Guro Aune
• Ingvild Vistad
• Vibeke Anett Ingebrigtsen
• Jenny Lifjeld
• Eli Sihn Samdal Steinskog
• Katarina Puco
• Sigmund Brabrand
• Pitt Niehusmann
• Åsmund Flobak
• Åse Haug
• Irja Alida Oppedal
• Sebastian Meltzer
• Egil Støre Blix
• Hege Elisabeth Giercksky Russnes
• Tormod Kyrre Guren
• Line Bjørge
• Åslaug Helland

Affiliation

• University of Bergen
• Stavanger Hospital Trust - Stavanger University Hospital
• University of Oslo
• Oslo University Hospital
• St. Olavs Hospital, Trondheim University Hospital
• Sørlandet Hospital Trust
• University Hospital of North Norway
• Bergen Hospital Trust - Haukeland University Hospital
• SINTEF Industry / Biotechnology and Nanomedicine
• Akershus University Hospital Trust
• UiT The Arctic University of Norway

External resources

• https://www.international-journal-of-gynecological-cancer.com/article/s1048-891x(24)06394-1/fulltext

DOI